Mutated bmp1b receptor as regulator of ovulation rate
OwnerTheresa Mary Wilson, Xi-Yang Wuinventors
Life of this patent
Estimating the term…
Abstract
The present invention is related to an isolated mutated nucleic acid molecule encoding the BMP1B receptor polypeptide. This molecule has a sequence which differs from that of the wild type BMP1B receptor polypeptide in that the codon encoding amino-acid residue 249 encodes arginine rather than glutamine, is able to hybridize under stringent conditions to the molecule above, is a variant of the molecule above, is a complement of any of the molecules above, or is an anti-sense sequence corresponding to any of the sequences in the molecules described above.
Claims44
An isolated mutated nucleic acid molecule encoding the BMP1B receptor polypeptide wherein the molecule:
- (a) has a sequence which differs from that of the wild type BMP1B receptor polypeptide in that the codon encoding amizno-acid residue 249 encodes arginine rather than glutamine;
- (b) is a non-wildtype variant of the sequence defined in (a) having an affect on modulation of ovulation;
- (c) is the complement of the molecule defined in (a) or (b)y or
- (d) is an anti-sense sequence corresponding to any of the sequences in (a)-(c);
An isolated BMP1B receptor polypeptide, having an amino acid sequence which differs from the wild type in that residue 249 is arginine not glutamine.
An isolated BMP1B receptor polypeptide having an amino acid sequence in which residue 249 is glutamine, but which is otherwise different from the wildtype BMP1B polypeptide sequence and which has the ability to modulate ovulation in a female mammal.
The use of SEQ ID No. 2 in the modulation of ovulation in a vertebrate.
A method of modulating the ovulation rate of a female vertebrate comprising the step of administering to said vertebrate an effective amount of mutated or wild type BMP1B receptor.
A method of reducing the ovulation of a female vertebrate comprising the step of administering an effective amount of an agent selected from the group consisting of:
- a) an immunising-effective amount of wild-type or mutated BMP1B receptor polypeptide, or an immunogenic region thereof;
- b) an antibody directed against wild-type or mutated BMP1B receptor polypeptide, or an antigen-binding fragment thereof;
- c) an antisense nucleic acid directed against nucleic acid encoding the mutated or wild-type BMP 1B receptor polypeptide;
- d) a pseudoreceptor to the wild-type or mutated BMP1B receptor;
- and
- e) a ligand which binds to the wild-type or mutated BMP1B receptor polypeptide, to thereby inhibit the activity of the endogenous BMP1B receptor of the vertebrate.
The use of a composition comprising an effective amount of agent selected from the group consisting of:
- (a) wild-type or mutated BMP1B receptor polypeptide, or an immunogenic region thereof:
- (b) an antibody directed against wild-type or mutated BMP1B receptor polypeptide, or an antigen-binding fragment thereof;
- (c) an antisense nucleic acid directed against nucleic acid encoding the mutated or wild-type BMP1B receptor polypeptide;
- (d) a pseudoreceptor to the wild-type or mutated BMP1B receptor;
- and
- (c) a ligand which binds to the wild-type or mutated BMP1B receptor polypeptide, to thereby inhibit the activity of the endogenous BMP1B receptor of the vertebrate;
- and a pharmaceutically or veterinarily acceptable carrier, to modulate the ovulation rate of a vertebrate.
A kit for identifying vertebrates which carry a mutated BMP1B receptor, said kit comprising:
- a) primer pairs for amplification of the appropriate region of the BMP1B receptor gene and optionally one or more of;
- b) buffer solution for the DNA amplification;
- c) a mixture of deoxynucleotides;
- d) means for DNA amplification;
- e) control DNA from the species being tested;
- f) appropriate standards;
- and
- g) a detection system.
A kit for detecting circulating mutated BMP1B receptor polypeptide in a vertebrate, wherein said kit comprises an antibody directed to the mutated polypeptide.
An isolated mutated nucleic acid molecule substantially as described herein with reference to any example, drawing or sequence listing thereof, relating to non wildtype nucleic acid molecules.
A method for identifying a vertebrate which carries a mutated BMP1B receptor nucleic acid molecule, substantially as described herein, with reference to any example and/or drawing thereof.
A genetic marker substantially as described herein with reference to any example. or drawing thereof.
An isolated mutated BMP1B receptor polypeptide substantially as described herein with reference to any example, drawing or sequence listing thereof.
A method of modulating the ovulation rate of a female vertebrate substantially as described herein with reference to any example and/or drawing thereof,
A composition comprising a mutated polypeptide substantially as described herein with reference to any example and/or drawing thereof.
A composition comprising a nucleic acid molecule substantially as described herein with reference to any example and/or drawing thereof, relating to non wildtype nucleic acid molecules.
A kit for identifying vertebrates carrying mutated BMP1B receptor substantially as described herein with reference to any example and/or drawing thereof.
Dependencies are inferred from the claim text.